Pharmacokinetics Study of CJ-30060 After Single Dose Administration in Health Male Volunteers
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
To compare the pharmacokinetics and safety after a single dose administration of CJ-30060 and
Exforge® 5/160mg, Crestor 10mg in healthy male volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
CJ HealthCare Corporation HK inno.N Corporation
Treatments:
Amlodipine Amlodipine, Valsartan Drug Combination Rosuvastatin Calcium Valsartan